STOCK TITAN

Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced a conference call on October 25, 2022, at 8:00 AM ET to discuss Astellas Pharma’s strategic investment in two gene therapy programs: TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN). This investment aims to bolster the development of AAV-based therapies targeting rare and large patient populations suffering from monogenic diseases of the central nervous system (CNS). For details, visit Taysha's webcast.

Positive
  • None.
Negative
  • None.

Conference call and webcast on Tuesday, October 25 at 8:00 AM ET

DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will host a conference call and webcast with slides to discuss Astellas Pharma’s strategic investment to support the development of two of Taysha’s AAV-based gene therapy programs, TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN), on Tuesday, October 25, 2022, at 8:00 AM Eastern Time.

Conference Call Details
Tuesday, October 25, at 8:00 AM Eastern Time / 7:00 AM Central Time
Toll Free:877-407-0792
International:201-689-8263
Conference ID:13734026
Webcast:https://ir.tayshagtx.com/news-events/events-presentations
  

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com


FAQ

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies is listed under the stock symbol TSHA.

When is Taysha Gene Therapies' conference call?

The conference call is scheduled for October 25, 2022, at 8:00 AM ET.

What will Taysha discuss during the conference call?

Taysha will discuss Astellas Pharma’s investment in TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy.

How can I access the Taysha conference call?

You can join the conference call by dialing 877-407-0792 toll-free or 201-689-8263 internationally.

What is the purpose of Astellas Pharma's investment in Taysha?

The investment supports the development of Taysha’s gene therapy programs targeting monogenic CNS diseases.

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Stock Data

379.15M
168.95M
17.54%
77.2%
7.69%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DALLAS